Welcome to E-Menai

" lipitor ambien KPA obtained exclusive U. and Canadian marketing rights for Cambia from Applied Pharma Research (APR), a Swiss drug delivery and drug development company, in 2005. About Migraine Migraine headaches affect an estimated 30 million people in the United States and disproportionately affect women 3 to 1. Its lead product, LIPOFEN® (fenofibrate capsules), is indicated as adjunctive therapy to diet to reduce elevated lipitor ambien triglycerides and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia. For more information about KPA, please visit www. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.